Ameridose

Ameridose was a pharmaceutical company based in the United States, known for providing sterile admixing and repackaging services to hospitals and healthcare providers. The company was founded in 2006 and was headquartered in Westborough, Massachusetts.

History

Ameridose was established with the aim of improving the efficiency and safety of medication delivery in healthcare settings. The company quickly grew to become a significant player in the pharmaceutical compounding industry, offering a wide range of products and services designed to meet the needs of hospitals and clinics.

In 2012, Ameridose came under scrutiny following a nationwide outbreak of fungal meningitis linked to contaminated steroid injections produced by the New England Compounding Center (NECC), a sister company. This led to increased regulatory oversight and a temporary shutdown of Ameridose's operations as the company worked to address safety concerns and improve its quality control processes.

Products and Services

Ameridose specialized in the sterile compounding of medications, which involves the preparation of customized pharmaceutical products to meet specific patient needs. The company provided a variety of services, including:

• Sterile Admixing: The preparation of sterile intravenous (IV) medications tailored to individual patient requirements.
• Repackaging: The repackaging of bulk medications into smaller, patient-specific doses to enhance safety and reduce waste.
• Custom Compounding: The creation of unique formulations for patients with specific medical needs that cannot be met by commercially available products.

Regulatory Challenges

The 2012 fungal meningitis outbreak had significant implications for Ameridose and the broader compounding pharmacy industry. The incident highlighted the need for stricter regulatory oversight and led to increased scrutiny from the U.S. Food and Drug Administration (FDA) and other regulatory bodies.

In response to these challenges, Ameridose implemented a series of measures to enhance its quality control systems and ensure compliance with regulatory standards. These efforts included upgrading its facilities, improving staff training, and adopting more rigorous testing procedures to ensure the safety and efficacy of its products.

Closure

Despite efforts to address regulatory concerns, Ameridose faced ongoing challenges in regaining the trust of healthcare providers and regulatory agencies. In 2014, the company announced its decision to cease operations permanently. The closure of Ameridose marked the end of a significant chapter in the history of pharmaceutical compounding in the United States.

Related Pages

• New England Compounding Center
• Pharmaceutical compounding
• Fungal meningitis outbreak
• U.S. Food and Drug Administration